1. A Novel Affibody-Auristatin E Conjugate With a Potent and Selective Activity Against HER2+ Cell Lines
   Alicja M. Sochaj-Gregorczyk et al, 2016, Journal of Immunotherapy CrossRef
2. Epithelial cell adhesion molecule‑targeting designed ankyrin repeat protein‑toxin fusion Ec1‑LoPE exhibits potent cytotoxic action in prostate cancer cells
   Tianqi Xu et al, 2022, Oncology Reports CrossRef
3. Potent and specific fusion toxins consisting of a HER2‑binding, ABD‑derived affinity protein, fused to truncated versions of Pseudomonas exotoxin�A
   Hao Liu et al, 2019, International Journal of Oncology CrossRef
4. Design and In Vitro Evaluation of a Cytotoxic Conjugate Based on the Anti-HER2 Affibody Fused to the Fc Fragment of IgG1
   Alicja Sochaj-Gregorczyk et al, 2017, International Journal of Molecular Sciences CrossRef
5. Design and fabrication of cell-targeted, dual drug-loaded nanoparticles with pH-controlled drug release and near-infrared light-induced photothermal effects
   Chang-Ching Weng et al, 2021, Materials & Design CrossRef
6. A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells
   Anna Serwotka-Suszczak et al, 2017, International Journal of Molecular Sciences CrossRef
7. HER2-Specific Pseudomonas Exotoxin A PE25 Based Fusions: Influence of Targeting Domain on Target Binding, Toxicity, and In Vivo Biodistribution
   Haozhong Ding et al, 2020, Pharmaceutics CrossRef
8. Recombinant immunotoxins development for HER2-based targeted cancer therapies
   Reza Mahmoudi et al, 2021, Cancer Cell International CrossRef
9. Affibody molecules as engineered protein drugs
   Fredrik Y Frejd et al, 2017, Experimental & Molecular Medicine CrossRef
10. Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL
    Rui Li et al, 2016, Journal of Controlled Release CrossRef
11. Purification and characterization of a long-acting ciliary neurotrophic factor via genetically fused with an albumin-binding domain
    Longfu Xu et al, 2017, Protein Expression and Purification CrossRef
12. Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors
    Mohamed Altai et al, 2018, Journal of Controlled Release CrossRef
13. Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model
    Tianqi Xu et al, 2021, Cancers CrossRef
14. Application of therapeutic protein-based fusion toxins
    Hyun-Jong Ahn et al, 2019, Molecular & Cellular Toxicology CrossRef
15. Immunotoxin IHP25-BT with low immunogenicity and off-target toxicity inhibits the growth and metastasis of trastuzumab-resistant tumor cells
    Rui Guo et al, 2021, International Journal of Pharmaceutics CrossRef
16. Near-infrared PbS quantum dots functionalized with affibodies and ZnPP for targeted imaging and therapeutic applications
    Ali W Al-Ani et al, 2021, Nano Express CrossRef
17. HER2-specific immunotoxins constructed based on single-domain antibodies and the improved toxin PE24X7
    Li Cao et al, 2020, International Journal of Pharmaceutics CrossRef
18. Fusion of an albumin-binding domain extends the half-life of immunotoxins
    Rui Guo et al, 2016, International Journal of Pharmaceutics CrossRef
19. Influence of molecular design on biodistribution and targeting properties of an Affibody-fused HER2-recognising anticancer toxin
    Mohamed Altai et al, 2016, International Journal of Oncology CrossRef
20. Affibody Molecules in Biotechnological and Medical Applications
    Stefan Ståhl et al, 2017, Trends in Biotechnology CrossRef